Andere talen Molecular Templates, Inc.

Aandelen

MTEM

US6085502085

Vertraagde tijd Nasdaq Andere beurzen 16:59:09 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,64 ^USD	+2,49%		+11,56%	-56,03%

12/04	Molecular Templates, Inc. Kondigt aan dat Maurizio Voi zijn functie als Chief Medical Officer zal neerleggen met ingang van 30 april 2024	CI
09/04	Molecular Templates, Inc. Presenteert tussentijdse gegevens van Mt-6402 Fase I-studie in patiënten met vaste tumoren met Pd-L1+ op de jaarlijkse bijeenkomst van de American Association for Cancer Research in 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	12/04
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism	09/04
Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	09/04
Molecular Templates, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update	29/03
Molecular Templates, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement	28/03
North American Morning Briefing: Investors Balance AI Hopes with Rate Concerns	18/03
Molecular Templates, Inc. Provides Interim Update	04/03
Molecular Templates, Inc. Provides Interim Update	04/03
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	08/02
Molecular Templates, Inc. Announces Board Changes	17/01
Molecular Templates, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q3 Revenue $6.8M	13/11
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update	13/11
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	02/11
Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	02/11
Molecular Templates to Participate in Upcoming Investor Conferences	01/11
Molecular Templates Names Chief Medical Officer	28-09-23
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer	28-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Molecular Templates, Inc.

Aandelen

MTEM

US6085502085

Andere talen

Filters